Non-ketotic hyperglycinaemia is a rare, often fatal disease caused by a defect in the glycine-cleavage reaction which yields carbon dioxide, methylene tetrahydrofolate, and ammonia. Surviving patients are usually severely mentally retarded. In this condition plasma glycine concentration is 2-5 times normal and urinary excretion increased 10-20-fold. Successful treatment has not been reported, though administration of sodium benzoate (to remove glycine by conjugation) or of methionine (to increase the supply of Ci-units) or by dietary restriction of glycine and serine can produce a temporary reduction in plasma glycine (Nyhan, 1974) .
A recent paper by Perry et al. (1975) has shown the absence of glycine cleavage in the brain of two patients with non-ketotic hyperglycinaemia.
The effects of the non-metabolisable amino-acid a-amincisobutyric acid (ar:AJB) on the transport of other amino-acids has been extensively investigated by Christensen and co-workers (summarised by Christensen and Cullen, 1968) . These workers have shown that the cellular transport of ar:AJB is similar to that of glycine. ar:AlB is taken up preferentially by the liver and to a lesser extent by muscle. Administration of ar:AlB to rats at a level of 1 g/kg body weight produced a reversible generalised aminoaciduria in which glycine and to a greater extent cystine, tyrosine, and lysine predominate.
More recently ar:AlB (140 mg/kg/24 h) has been given experimentally to patients with homocystinuria to increase the urinary excretion of homocystine (Falchuk et aI., 1973) .
CLINICAL DETAILS
The patient is the third child of unrelated healthy parents. During the neonatal period his mother observed infrequent episodes of rigidity and stiffness with twitching and that he was a slow feeder On admission to Warwick General Hospital at 14 weeks a provisional diagnosis of hyperglycinaemia was made. The baby was referred to the Hospital for Sick Children, where the hyperglycinaemia (798 /Lmol/ litre) and glycinuria were confirmed. Abnormal excretion of volatile and non-volatile organic acids has never been observed either on normal diet, during loading tests (100 mgjkg) of protein, glycine, leucine, and isoleucine, or during the trial of ar:ATB.
At 10 months marked mental retardation and hypotonia were confirmed but physical development was normal. Although fits were previously well controlled, a protein load was followed by three fits. During the glycine load the plasma concentration of glycine rose from a fasting value of 494 /Lmol/litre to a maximum value of 1194 /Lmol/litre at 2 h; the patient had a fit at 2.5 h, when the concentration was 1134 /Lmol/litre. The concentration of serine fell slightly during the test from a fasting value of 126 to 122 /Lmol/litre. A loading dose of 3,4-dihydroxybenzoic acid (20 rng/kg) resulted in a normal excretion of vanillic acid and vanilloylglycine.
EFFECT OF nAJB-RESULTS AND DISCUSSION
The purpose of the investigation was carefully explained to the parents of the patient. Because the parents were anxious to conduct the investigation at home accurately timed collection of urine was not possible, and comparisons were therefore based on creatinine excretion during the five weeks of the trial.
Blood samples were taken and most urine samples collected in the afternoon when the action of ar:AIB and the concentration of glycine were expected to be maximal. ar:AlB (100 mg/kg body weight) was given three times daily.
Apart from the expected elevated excretions of glycine and ar:AJB no qualitative changes were observed in the amino-acid chromatogram, and no increase in cystine excretion was detected by the nitroprusside test. The Table summarises quantitative data on urinary and plasma amino-acids. The concentrations of plasma amino-acids apart from glycine were in the normal range throughout the period of investigation.
Although at first the parents thought that the patient was improved, this was not substantiated by a later single blind control of therapy. There were insignificant changes in the EEG.
While the clinical response to therapy with ar:AJB 144 
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III lStudenfs t test t = 3.33 for 14 degrees of freedom. IF (variance ratio) = 6.54 for P = 0.01, 1 = 11; a = 7. "Corrected for unequal variances.
There was no correlation between the excretion of glycine and aAlB. Plasma: C.S.F. amino-acid concentration ratio before administration of nAIR was 4.25. during administration was 4.85. Ratio in normal subjects greater than 3D, in patients with non-ketotic hypcrglycinaemia less than 5. Only a trace amount of nAIB was detected in plasma during treatment. 40Baselinecollection coincided with a heat wave. hence concentrated urine specimens.
was disappointing, the absence of adverse effects over the five-week period warrants a trial of exAIB in patients diagnosed in the neonatal period before irreversible brain damage has occurred but at a time when plasma glycine would be elevated (reflecting high protein intake). The ready methylation of 3,4dihydroxybenzoic acid to vanillic acid and its glycine conjugate make it unlikely that deficiency of C, units, formed during glycine cleavage, is a cause of symptoms in this disease.
The patient was under the care of Dr. John Wilson while at the Hospital for Sick Children. The authors thank him for his advice and encouragement.
